Carroll G J, Will R K, Peter J B, Garlepp M J, Dawkins R L
Department of Clinical Immunology, Royal Perth Hospital, Western Australia.
J Rheumatol. 1987 Oct;14(5):995-1001.
Eight Australian cases of D-penicillamine induced polymyositis/dermatomyositis (PM/DM) are reported. In terms of clinical, pathological and electromyographic features, D-penicillamine PM/DM is similar to idiopathic PM/DM but is generally less severe. Recovery is usually rapid when D-penicillamine is withdrawn. Sera were available for study in 6 of the 8 reported cases. Two of the 6 had elevated titers of acetylcholine receptor autoantibodies. Neither of these patients had clinical signs of myasthenia gravis. In 3 of 6 patients typed for C2, no bands were detected suggesting homozygous C2 deficiency. D-penicillamine PM/DM is associated with HLA-B18, B35 and DR4 and is immunogenetically different from idiopathic PM/DM, rheumatoid arthritis and D-penicillamine myasthenia gravis.
本文报告了8例澳大利亚的由青霉胺诱发的多发性肌炎/皮肌炎(PM/DM)病例。就临床、病理及肌电图特征而言,青霉胺诱发的PM/DM与特发性PM/DM相似,但通常病情较轻。停用青霉胺后,恢复通常较快。在报告的8例病例中,有6例血清可供研究。6例中有2例乙酰胆碱受体自身抗体滴度升高。这两名患者均无重症肌无力的临床体征。在6例进行C2分型的患者中,有3例未检测到条带,提示纯合子C2缺乏。青霉胺诱发的PM/DM与HLA - B18、B35和DR4相关,在免疫遗传学上与特发性PM/DM、类风湿性关节炎及青霉胺诱发的重症肌无力不同。